Spots Global Cancer Trial Database for Phase I Study of P276-00 in Patients With Advanced Refractory Neoplasms
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Phase I Study of P276-00 in Patients With Advanced Refractory Neoplasms
Official Title: An Open Label Multicentric Phase 1 Study of Selective Cyclin Dependent Kinase Inhibitor P276-00 in Patients With Advanced Refractory Neoplasms
Study ID: NCT00408018
Conditions
Interventions
Study Description
Brief Summary: P276-00 is a molecule derived from Rohitukine, which through pre clinical assays was identified as a selective Cdk4-D1 and Cdk1-B inhibitor.The inhibition of these Cdks causes cell cycle arrest between the G1-S transition thus blocking the cell cycle events at an early stage of development. It therefore has the potential for being efficacious with lesser side effects.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Nizam's Institute of Medicai Sciences, Hyderabaad, Andhra Pradesh, India
Global Hospital, Hyderabad, Andhra Pradesh, India
Tata Memorial Hospital, Mumbai, Maharashtra, India
Contact Details
Name: Purvish M parikh, MD, DNB, PhD
Affiliation: Tata Memorial Hospital
Role: PRINCIPAL_INVESTIGATOR
Name: Raghunadharao D, MD, DM
Affiliation: Nizam's Institute of Medical Sciences
Role: PRINCIPAL_INVESTIGATOR
Name: Ravikumar Saxena, MD
Affiliation: Global Hospital
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
